UNSPSC 51201523: Anakinra

This classification denotes an interleukin-1 receptor antagonist with the molecular formula C759H1186N208O232S10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9013DUQ28K, more generally known as anakinra. European Medicines Agency schedules anakinra in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05500MIG. The term ANAKINRA is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.

ANAKINRA is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anakinra under HS 30021095 and SITC 54163. As of Q4 2014, ANAKINRA remains the US FDA Preferred Term for this commodity. Anakinra bears US NLM identifiers UMLS ID C0245109 and NCI Concept Code C38717. SMILES: none.

UNSPSC 51201523 Anakinra (Commodity) appears in state and local solicitations with minimal coherence to the code's nominal scope — anakinra is a biopharmaceutical treatment for rheumatoid arthritis and other autoinflammatory conditions, yet recent opportunities tagged to this code span unrelated work including a canine acquisition, athletic training services, and medical first-aid supply procurement. The code shows little relevant recent activity aligned with its intended product category.

The three recent opportunities posted between April and July 2026 — Washington County, Oregon's request for a District Attorney's Office Dog (RFP due August 14, 2026), the City of Tucson's RFP for Athletic Training Services for the Tucson Fire and Police Departments (due June 9, 2026), and the City of Tampa Fire Rescue Department's Invitation to Bid for medical aid supplies including antiseptic sprays, hydrogen peroxide, and first aid kits (ITB 25-P-00157, bid opening April 9, 2025) — are neither pharmaceutical procurement nor aligned with anakinra procurement practices. The mismatch between the code's pharmaceutical designation and the actual work being solicited under it suggests either miscoding by issuing bodies or a data integrity issue in the opportunity records themselves. Entities pursuing work under this code should verify the actual commodity classification with issuing bodies before investment in pursuit, as the opportunities currently associated with UNSPSC 51201523 do not reflect biopharmaceutical procurement activity.